Previous 10 | Next 10 |
Shares of Syndax Pharmaceuticals ( SNDX ) have fallen by 12% since my article from January of last year stated that the company was in for a potentially transformative 2018. So far in 2019, the stock has posted a 95% gain as optimism returned to the name as Wall Street focuses on renewed pro...
WALTHAM, Mass. , June 13, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger , President and Chief Op...
GAITHERSBURG, Md. , May 28, 2019 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the appointment of Allan L. Shaw , CPA, as the company's Chief Financial Offi...
The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with this Read more ...
WALTHAM, Mass. , May 14, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison , M.D., Chief Executi...
The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more ...
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2019 Earnings Release and Conference Call May 6, 2019 4:30 PM ET Company Participants Melissa Forst – Argot Partners-Vice President Briggs Morrison – Chief Executive Officer Michael Metzger – President and Chief Operatin...
Gainers: SEDG +18.5% . AVID +10.2% . APT +9.3% . AIG +6.4% . LCI +5.7% . More news on: SolarEdge Technologies, Inc., Avid Technology, Inc., Alpha Pro Tech, Ltd., Stocks on the move, Read more ...
Syndax Pharmaceuticals (NASDAQ: SNDX ): Q1 GAAP EPS of -$0.53 beats by $0.02 . More news on: Syndax Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
WALTHAM, Mass. , May 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended March 31, 2019 . In addition, the C...
News, Short Squeeze, Breakout and More Instantly...
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia PR Newswire – New PDUFA action date of December 26, 2024 allows FDA additional time to complete their review – WALTHAM, Mass. , ...
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire WALTHAM, Mass. , July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...